Cargando…

1490. Vancomycin 125 mg vs. 250 mg for the Treatment of Non-Severe and Severe Clostridium difficile Infections

BACKGROUND: Infectious Diseases Society of America (IDSA) guidelines recommend oral vancomycin 125 mg four times daily for 10 to 14 days for both non-severe and severe Clostridium difficile infections (CDI). Although 125 mg achieves sufficient fecal concentrations, doses of 250 mg are still commonly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Amy, Richardson, Caitlin, Kuriyama, Steve M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810539/ http://dx.doi.org/10.1093/ofid/ofz360.1354

Ejemplares similares

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

1125. Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalized adults with severe COVID-19 pneumonia: an open-label randomized trial.
por: Gutierrez, Carlos Dueñas, et al.
Publicado: (2022)

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
por: Leo, Angelo Di, et al.
Publicado: (2013)

488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
por: Vega, Ana, et al.
Publicado: (2018)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Comparative Effectiveness of Vancomycin vs. Metronidazole in Mild Clostridium difficile Infections, and Potential Impact on Subsequent Vancomycin-Resistant Enterococcus (VRE) Isolation
por: Youngster, Ilan, et al.
Publicado: (2017)

1652 Retrospective Comparision of Oral Vancomycin Capsules vs Oral Vancomycin Solution for the Treatment of Severe Clostridium Defficile Infection
por: Saleh, Rania, et al.
Publicado: (2014)

The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series
por: Akamine, Christine M., et al.
Publicado: (2016)

1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
por: Moran, Gisele, et al.
Publicado: (2018)

1490. Lymphogranuloma Venereum: Correct Diagnosis Makes All the Differences
por: Sandhu, Avnish, et al.
Publicado: (2018)

1490. Predictors of Early Mortality in HIV-associated Tuberculous Meningitis
por: Kagimu, Enock, et al.
Publicado: (2023)

502. Enhanced Sporulation and Vancomycin Resistance Associated With Clostridium difficile From Recurrent Infections
por: Tijerina-Rodriguez, Laura E, et al.
Publicado: (2018)

673 Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2014)

Intracolonic Administration of Vancomycin in Intensive Care Unit Patients with Severe Clostridium Difficile Colitis
por: Teixeira, Alex, et al.
Publicado: (2020)

1497. Relapsing Clostridium difficile Infection: Resolution with Combined Patient Choice Fecal Microbiota Transplantation, Vancomycin Taper, and Vancomycin Suppression
por: Shadowen, Rebecca D, et al.
Publicado: (2019)

2415. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infections among High-risk Patients
por: Lew, Alison, et al.
Publicado: (2019)

2355. The Association Between Diagnostic Testing Method and Clostridium difficile Infection Severity
por: Menon, Anitha, et al.
Publicado: (2019)

A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity
por: Di, Xiuzhen, et al.
Publicado: (2015)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

1980. Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
por: Tirmizi, Samad, et al.
Publicado: (2018)

1110. A multicenter Evaluation of Outcomes Associated With Oral Vancomycin Dose in Patients With Clostridium difficile Infection
por: Bidell, Monique, et al.
Publicado: (2018)

2236. Stool-Derived Inflammatory Mediators Serve as Biomarkers of Severity in Clostridium difficile Infection
por: Motyka, Jonathan, et al.
Publicado: (2019)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection
por: Malamood, Mark, et al.
Publicado: (2015)

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

Discordance of SHEA/IDSA Clostridium difficile Disease Severity Scale in Solid Organ Transplant Patients
por: Lee, Tiffany, et al.
Publicado: (2017)

487. Severity and Clinical Outcomes of Clostridium difficile Infection Based on Toxin B Assay Results
por: Kamimoto, Jorge Jo, et al.
Publicado: (2018)

76. Validation of Systemic Inflammatory Mediators as Biomarkers for Severity and Adverse Outcomes in Clostridium difficile Infection
por: Dieterle, Michael G, et al.
Publicado: (2019)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

1651 Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013)

Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?
por: Sardana, Kabir, et al.
Publicado: (2017)

Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection
por: Britt, Nicholas S., et al.
Publicado: (2014)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
por: Bunnell, Kristen L., et al.
Publicado: (2017)

Concomitant Vancomycin-Resistant Enterococcus faecium and Clostridium difficile Colitis
por: Mehershahi, Shehriyar, et al.
Publicado: (2021)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

The Severity of Depressive Symptoms vs. Serum Mg and Zn Levels in Postmenopausal Women
por: Stanisławska, M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4t977ip89k94qddkds8sd1uvco